Application of a new method for detecting the phenotype of target binding cells.
A new method was developed for detecting the phenotype of target binding cells (TBC) in a single-cell assay system. This methodology was evaluated during a clinical trial of recombinant interferon alfa-2a (rIFN alfa-2a) for the treatment of 10 metastatic renal cell carcinoma patients. Total TBC with K562 targets, HNK-1+ TBC, and HLA-DR+ TBC were quantitated during rIFN alfa-2a therapy. A significantly increased proportion of lymphocytes bound to target cells on day 9 of therapy bore the HNK-1 marker. This proportion subsequently declined to pretreatment levels. Total TBC paralleled the rise and fall in HNK-1+ TBC. HLA-DR+ TBC binding to targets remained constant and low throughout therapy. These findings suggest that rIFN alfa-2a early in therapy (day 9) caused the recruitment of additional HNK-1+ cells into binders. However, with continued therapy, this proportion reverts to pretreatment levels. The results of this clinical trial served to illustrate the ability of the modified single-cell assay system to detect TBC phenotype.
Lindemann
R A
RA
Departments of Surgery/Oncology, UCLA School of Medicine.
Jenkins
J A
JA
Figlin
R A
RA
Golub
S H
SH
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface / Q000032:analysis*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000473:pathology; D003601:Cytotoxicity Tests, Immunologic / Q000379:methods*; D006801:Humans; D007124:Immunoenzyme Techniques; D007370:Interferon Type I / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology; D007694:Killer Cells, Natural / Q000032:analysis*; D010641:Phenotype; D011994:Recombinant Proteins / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D007370:Interferon Type I; D011994:Recombinant Proteins